Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Company Profile CanAlaska Uranium Ltd. V.CVV

Alternate Symbol(s):  CVVUF

Energy
CanAlaska Uranium Ltd. is a Canada-based company, which is engaged in the exploration of uranium, nickel and diamond properties. The Company holds interests in approximately 350,000 hectares (865,000 acres), strategically located in the eastern Athabasca Basin. The Company also holds properties prospective for nickel, copper, gold and diamonds. The Company’s projects include West McArthur, Key... see more

Showcase News Releases

Showcase news

Silvercorp Metals Inc.
Silvercorp Reports Operational Results and Financial Results Release Date for Fiscal 2024, and Issues Fiscal 2025 Production, Cash Costs, and Capital Expenditure Guidance
Nextech3D.ai
Nextech3D.ai Receives Notice From USPTO to be Granted Patent for CAD 3D Model Part Assembly & Segmentation
Revive Therapeutics Ltd.
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

More Showcase News Releases »